Treatment of post-coarctectomy hypertension with labetalol: a 9-year single-center experience

Siersma, C.; Brouwer, C.N.M.; Sojak, V.; Harkel, A.D.J. ten; Roeleveld, P.P. (2022)

Article / Letter to editor

Background: Although considering the pathophysiology of post-coarctectomy hypertension, beta-blockers should be effective, experience with labetalol for treatment is limited in the literature. Methods: Retrospective collection and analysis of data in children aged <= 6 years following coarctectomy in our tertiary care university medical center between January 2009 and June 2018. Results: 96 patients were included, 45 were treated with intravenous labetalol and 51 received no treatment. Median time to maximum dose received (median 1.1 mg/kg/h) was 2.7 h, and median time to the reduction of labetalol dose was 8.3 h. No antihypertensives had to be added. In one child, labetalol was switched to nitroprusside due to bronchoconstriction. Of patients receiving intravenous labetalol, 48% had been switched to oral labetalol at discharge. Conclusions: Intravenous labetalol is a fast, effective, and safe drug to treat hypertension following aortic coarctation repair. Labetalol is easily converted to oral therapy when the continuation of treatment is considered necessary.

• aortic operation
• coarctation
• congenital heart surgery
• database
• intensive care
• pediatric

• All authors: Siersma, C.; Brouwer, C.N.M.; Sojak, V.; Harkel, A.D.J. ten; Roeleveld, P.P.
• Date: 2022-11-01
• Journal: World Journal for Pediatric and Congenital Heart Surgery
• Volume: 13
• Issue: 6
• Pages: 701 - 706
• DOI: doi:10.1177/21501351221111797
• Link: https://journals.sagepub.com/doi/10.1177/21501351221111797